Who We Are
Object Pharma is an innovative fully integrated biopharma company dedicated to the development of new therapies for the treatment of mental illness. Our first indication is Major Depressive Disorder (MDD).
Object Pharma has a revenue generating division, called Metabiologics, that sells critical reagents to the botulinum neurotoxin community. These sales have allowed Object Pharma to self-fund the preclinical stage of our first product candidate, OP01.
health crisis in our lifetime.
treatments for mental health.
Our Team
Kenton Abel, PhD
CEO
Dan Radecki, MA, PhD
President
Aaron Chamberlian, PhD
CSO
Mike Goodnough, PhD, EVP
EVP, Toxin Production
Eric Chojnicki, PhD, MBA
Vice President of Product Development
David Parker
Independent Director
Scientific Advisors
Michelle Magid, MD, MBA
President of Austin PsychCare, PA in Austin, Texas. Associate professor for the University of Texas Dell Medical School and for the Texas A&M Health Science Center
Michael E. Thase, MD
Professor, Psychiatry, Departments of Psychiatry, Perelman School of Medicine at the University of Pennsylvania
Steve Yoelin, MD
Leading practitioner, researcher, and trainer of neuromodulators, dermal fillers, and other medical aesthetic products in the United States with a successful private practice in Newport Beach, CA.